Skip to main content

Merck & Co., Inc.

corporate_fare Company Profile

Merck & Co., Inc.

MRK·NYSE·Life Sciences·CIK 0000310158

Merck & Co., Inc. is a global healthcare company providing innovative health solutions through prescription medicines, including biologic therapies, vaccines, and animal health products. The company manages its operations primarily on a product basis, with two reportable operating segments: Pharmaceutical and Animal Health. The Pharmaceutical segment encompasses human health pharmaceutical and vaccine products. Human health pharmaceutical products are therapeutic and preventive agents, generally sold by prescription, for treating human disorders. Merck sells these products mainly to drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers like health maintenance organizations and pharmacy benefit managers. Human health vaccine products include preventive pediatric, adolescent, and adult vaccines, sold primarily to physicians, wholesalers, distributors, and government entities. The Animal Health segment focuses on discovering, developing, manufacturing, and marketing a broad range of veterinary pharmaceutical and vaccine products, alongside health management solutions and services. These offerings aim to prevent, treat, and control diseases in all major livestock and companion animal species. This segment also provides a comprehensive suite of digitally connected identification, traceability, and monitoring products. Merck sells its animal health products to veterinarians, distributors, animal producers, farmers, and pet owners.

Merck & Co., Inc. (NYSE:MRK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 66 items for MRK at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Merck's Welireg-Keytruda Combo Gets Priority FDA Review, June PDUFA Date
  • Merck's Welireg-Lenvima Combo Cuts Cancer Progression Risk by 30%; FDA Accepts NDAs
  • Keytruda/Padcev Combo Slashes Bladder Cancer Progression Risk by 47% in Phase 3 Trial
  • Merck's Keytruda Combo Significantly Improves Ovarian Cancer Survival
  • Merck Reports Solid 2025 Financials, Advances Pipeline Amidst Keytruda Patent & IRA Headwinds, and Announces Major Restructuring

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$65.01B
Net Income
$18.25B
Diluted EPS
$7.28
Op. Cash Flow
$16.47B
Free Cash Flow
$12.36B
Gross Profit
$48.63B
Cash & Equivalents
$14.56B
Total Debt
$49.05B
Debt / Equity
0.93×
Net Margin
28.1%
Shares Outstanding
2.5B sh
Source: 10-K · filed 2026-02-24 · accession 0000310158-26-000063
$141.6 -0.22% today
52-week range · as of 2026-08-07 $77.58 – $141.6
Market cap
$349.35B
Volume
1.7M (0.2× avg)
3-mo avg 10.2M
Live data · 2026-10-28 15:34 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MRK - Filings & News (Page 4)

MRK
Feb 28, 2026, 10:08 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $123.31
Real-time Price: $141.60 info
Change: +$18.29 (+15%) info
Market Cap: $349.352B info
MRK
Feb 28, 2026, 10:03 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $123.31
Real-time Price: $141.60 info
Change: +$18.29 (+15%) info
Market Cap: $349.352B info
MRK
Feb 27, 2026, 10:28 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $121.49
Real-time Price: $141.60 info
Change: +$20.11 (+17%) info
Market Cap: $349.352B info
MRK
Feb 27, 2026, 10:24 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $121.41
Real-time Price: $141.60 info
Change: +$20.19 (+17%) info
Market Cap: $349.352B info
MRK
Feb 24, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $124.00
Real-time Price: $141.60 info
Change: +$17.60 (+14%) info
Market Cap: $349.352B info
MRK
Feb 03, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $112.00
Real-time Price: $141.60 info
Change: +$29.60 (+26%) info
Market Cap: $349.352B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets